Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Director Buys $100,001.20 in Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTXGet Free Report) Director Don M. Bailey acquired 96,155 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average cost of $1.04 per share, with a total value of $100,001.20. Following the completion of the acquisition, the director now owns 158,801 shares of the company’s stock, valued at $165,153.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Lineage Cell Therapeutics Price Performance

Shares of LCTX stock opened at $1.08 on Friday. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.84 and a 52 week high of $1.57. The company has a market capitalization of $188.99 million, a price-to-earnings ratio of -8.31 and a beta of 1.23.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTXGet Free Report) last issued its earnings results on Thursday, November 9th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The company had revenue of $1.25 million during the quarter, compared to the consensus estimate of $3.30 million. Lineage Cell Therapeutics had a negative return on equity of 33.08% and a negative net margin of 262.94%. On average, analysts predict that Lineage Cell Therapeutics, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $6.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, February 5th.

Check Out Our Latest Research Report on Lineage Cell Therapeutics

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 13.5% during the second quarter. Fort Sheridan Advisors LLC now owns 83,931 shares of the company’s stock worth $118,000 after buying an additional 10,000 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Lineage Cell Therapeutics by 18.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 72,400 shares of the company’s stock worth $114,000 after purchasing an additional 11,309 shares during the period. SG Americas Securities LLC lifted its position in Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock worth $34,000 after purchasing an additional 11,779 shares during the period. Barclays PLC lifted its position in Lineage Cell Therapeutics by 87.3% in the second quarter. Barclays PLC now owns 25,905 shares of the company’s stock worth $36,000 after purchasing an additional 12,075 shares during the period. Finally, Geode Capital Management LLC lifted its position in Lineage Cell Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,264,409 shares of the company’s stock worth $1,479,000 after purchasing an additional 13,253 shares during the period. 43.42% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

(Get Free Report)

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Read More

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.